For reference, the NSABP FB-10 phase Ib/II trial also evaluated T-DM1-based combinations in patients with metastatic HER2-positive breast cancer, reporting an ORR of 32% in the phase II portion. This evidence concerns the gene ERBB2 and breast carcinoma.